Bioretec announces that its RemeOs™ Screw has received Transitional Pass-Through Payment approval from CMS, enhancing its orthopedic offerings.

Bioretec Ltd. has received CE mark approval for its RemeOs™ Trauma Screw product group, paving the way for global expansion and improved patient outcomes.

Bioretec Ltd has officially notified the market about a significant increase in shareholding by Sp-Rahastoyhtiö Oy, surpassing 5%.

Bioretec Ltd recently held a constitutive meeting of its Board of Directors, making important appointments and confirming member independence.

Bioretec Ltd's Q1 2026 review highlights early successes from strategic realignments, showcasing increased net sales and operational efficiency.

Bioretec Ltd recently held an Extraordinary General Meeting, making significant decisions regarding share offerings and the company's future financial strategy.

Discover the recent manager transactions at Bioretec Oy, including insights from Jordy Winters regarding share acquisitions and the company's groundbreaking developments in orthopedic care.

Bioretec Ltd is set to commence negotiations focused on streamlining operations to boost efficiency and profitability, affecting its production team in Finland.

Discover the significant resolutions and elections made during Bioretec Ltd's Annual General Meeting in 2026, reflecting on key aspects including financial decisions and board appointments.

Explore the latest managerial transactions from Bioretec Oy and their innovative advancements in biodegradable orthopedic implants, enhancing patient care.

Bioretec Ltd Press release 22 November 2024 at 9:30 a.m.EET TAMPERE, Finland, Nov. 22, 2024 /PRNewswire/ -- Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB), which is a distributor of medical and surgical products based in New Jersey.

Bioretec Ltd. unveils its quarter one 2026 business review, highlighting early success from its renewed strategy and operational improvements in key markets.

Bioretec Ltd has registered 60,000 new shares via the option rights program 2018-1A, enhancing its capacity in the global orthopedic market.

Bioretec Ltd's financial results for 2024 reveal significant growth and strategic advancements in the orthopedic sector, paving the way for future innovations.

Bioretec has announced changes to its financial goals for 2026-2028, emphasizing an adjusted sales margin to align with industry standards, enhancing transparency.

Explore the significant proposals from Bioretec Ltd's Shareholders' Nomination Board ahead of the 2025 Annual General Meeting, including board member roles.

Bioretec Ltd's Board has approved a new stock option plan aimed at incentivizing key personnel. This initiative seeks to enhance long-term shareholder value and employee commitment.

Orthopedic implant manufacturer Bioretec has received a Breakthrough Device Designation by the FDA for its RemeOs DrillPin.  The magnesium alloy, biodegradable device is used for the fixation of bone fragments in pediatric and adult patients, according to a Dec. 14 news release from Bioretec.  The DrillPin is also used in the treatment of epi-metaphyseal fractures […]

The 2026 Annual General Meeting of Bioretec Ltd outlines major decisions including board re-elections, financial resolutions, and future auditing plans.

Bioretec Ltd has finalized its rights issue, registering over 1.2 billion new shares in a significant step forward. Discover what this means for the company and its innovative healthcare solutions.

Bioretec Ltd has successfully completed its rights issue, resulting in the registration of over 1.2 billion new shares, boosting its market presence and investor engagement.